Lipid formulations of amphotericin B preserve and stabilize renal function in HSCT recipients

Bone Marrow Transplantation

Volumn 33, Issue 5, 2004, Pages 543-548

  Miller, C B ^a   Waller, E K ^b   Klingemann, H G ^c   Dignani, M C ^d   Anaissie, E J ^d   Cagnoni, P J ^e   McSweeney, P ^e   Fleck, P R ^f   Fruchtman, S M ^g   McGuirk, J ^h   Chao, N J ⁱ  

^a St Agnes Healthcare   (United States)

^b EMORY UNIVERSITY   (United States)

^c RUSH UNIVERSITY MEDICAL CENTER   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f Cincinnati Transplant Institute   (United States)

^g Mount Sinai Medical Center   (United States)

^h Oncol/Hematol Assoc Kansas City   (United States)

ⁱ DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

AmBisome; Amphotericin B; Fungal infections; Hematopoietic stem cell transplant; Nephrotoxicity; Renal function

Indexed keywords

AMIKACIN; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B DEOXYCHOLATE; AMPHOTERICIN B LIPID COMPLEX; CREATININE; CYCLOSPORIN; FOSCARNET; GENTAMICIN; TACROLIMUS; TOBRAMYCIN;

ADULT; AGED; ARTICLE; CAUSE OF DEATH; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CREATININE BLOOD LEVEL; DRUG EFFECT; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMODIALYSIS; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; MORTALITY; MYCOSIS; NEPHROTOXICITY; PRIORITY JOURNAL; RECIPIENT; RISK ASSESSMENT; STATISTICAL MODEL;

ADULT; AMPHOTERICIN B; ANTIFUNGAL AGENTS; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; KIDNEY; KIDNEY DISEASES; LIPOSOMES; MALE; MIDDLE AGED; MYCOSES; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES;

EID: 12144289618     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704408     Document Type: Article

References (27)

1. Gallis HA, Drew RH, Pickard WW. Amphotericin B: 30 years of clinical experience. Rev Infect Dis 1990; 12: 308-329.
2. Wingard JR, Kubilis P, Lee L et al. Clinical significance of nephrotoxicity in patients treated with amphotericin B for suspected or proven aspergillosis. Clin Infect Dis 1999; 29: 1402-1407.
3. Luber AD, Maa L, Lam M, Guglielmo BJ. Risk factors for amphotericin B-induced nephrotoxicity. J Antimicrob Chemother 1999; 43: 267-271.
4. Clements Jr JS, Peacock Jr JE. Amphotericin B revisited: reassessment of toxicity. Am J Med 1990; 88: 22N-27N.
5. Hiemenz JW, Walsh TJ. Lipid formulations of amphotericin B: recent progress and future directions. Clin Infect Dis 1996; 22 (Suppl. 2): S133-S144.
6. Walsh TJ, Finberg RW, Arndt C et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med 1999; 340: 764-771.
7. White MH, Bowden RA, Sandler ES et al. Randomized, double-blind clinical trial of amphotericin B colloidal dispersion vs amphotericin B in the empirical treatment of fever and neutropenia. Clin Infect Dis 1998; 27: 296-302.
8. Prentice HG, Hann IM, Herbrecht R et al. A randomized comparison of liposomal versus conventional amphotericin B for the treatment of pyrexia of unknown origin in neutropenic patients. Br J Haematol 1997; 98: 711-718.
9. Rex JH, Walsh TJ. Estimating the true cost of amphotericin B. Clin Infect Dis 1999; 29: 1408-1410, (editorial response).
10. Denning DW, Lee JY, Hostetler JS et al. NIAID Mycoses Study Group Multicenter trial of oral itraconazole therapy for invasive aspergillosis. Am J Med 1994; 97: 135-144.
11. Stevens DA, Lee JY. Analysis of compassionate use itraconazole therapy for invasive aspergillosis by the NIAID Mycoses Study Group criteria. Arch Intern Med 1997; 157: 1857-1862.
12. Barrett JP, Vardulaki KA, Conlon C et al. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. Clin Ther 2003; 25: 1295-1320.
13. Graybill JR, Tollemar J, Torres-Rodriguez JM et al. Antifungal compounds: Controversies, queries and conclusions. Med Mycol 2000; 38 (Suppl. 1): 323-333.
14. Quilitz RE, Arnold AD, Briones GR et al. Practice guidelines for lipid-based amphotericin B in stem cell transplant recipients. Ann Pharmacother 2001; 35: 206-216.
15. Harbarth S, Burke JP, Lloyd JF et al. Clinical and economic outcomes of conventional amphotericin B-associated nephrotoxicity. Clin Infect Dis 2002; 35: E120-e127.
16. Gubbins PO, Penzak SR, Polston S et al. Characterizing and predicting amphotericin B-associated nephrotoxicity in bone marrow or peripheral blood stem cell transplant recipients. Pharmacotherapy 2002; 22: 961-971.
17. Deray G. Amphotericin B nephrotoxicity. J Antimicrob Chemother 2002; 49 (Suppl. 1): 37-41.
18. Patterson TF. Current and future approaches to antifungal therapy. Curr Opin Infect Dis 2000; 13: 579-581.
19. Cagnoni PJ, Walsh TJ, Prendergast MM et al. Pharmaco-economic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Clin Oncol 2000; 18: 2476-2483.
20. Wingard JR. Lipid formulations of amphotericins: Are you a lumper or a splitter? Clin Infect Dis 2002; 35: 891-895.
21. Bates DW, Su L, Yu DT et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis 2001; 32: 686-693.
22. O'Connell B, Craig JI, Marcus RE, Ludlam H. Cost-effective use of liposomal amphotericin B. Clin Lab Haematol 2002; 24: 317-319, (letter)..
23. Walsh TJ, Yeldandi V, McEvoy M et al. Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients. Antimicrob Agents Chemother 1998; 42: 2391-2398.
24. Wingard JR. Efficacy of amphotericin B lipid complex injection (ABLC) in bone marrow transplant recipients with life-threatening systemic mycoses. Bone Marrow Transplant 1997; 19: 343-347.
25. Wingard JR, White MH, Anaissie E et al. A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph/ABLC Collaborative Study Group. Clin Infect Dis 2000; 31: 1155-1163.
26. Boswell GW, Buell D, Bekersky I. AmBisome (liposomal amphotericin B): A comparative review. J Clin Pharmacol 1998; 38: 583-592.
27. Walsh TJ, Goodman JL, Pappas P et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrob Agents Chemother 2001; 45: 3487-3496.